← Eichor
Condition: Myeloablative Allogeneic Hematopoietic Cell Transplantation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myeloablative Allogeneic Hematopoietic Cell Transplantation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation
NA · 1 location(s) · Dana-Farber Cancer Institute · NCT05335434Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Vir
Phase 4 · 1 location(s) · Beijing Children's Hospital · NCT07029958Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY
NA · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07183878Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (
Phase 2 · 1 location(s) · Hannah Choe, MD · NCT07249346Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients
Phase 3 · 1 location(s) · King Faisal Specialist Hospital & Research Center · NCT04314219Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
Phase 2 · 1 location(s) · University of Alabama at Birmingham · NCT06315309Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched
Phase 2 · 1 location(s) · University of Illinois at Chicago · NCT06802315Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05327023A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil
Phase 3 · 30 location(s) · Incyte Corporation · NCT06615050Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant
Phase 2 · 1 location(s) · Tata Memorial Centre · NCT07709195Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adul
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT06128070
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.